Gastroenterology: RHB-1015, A Triple Drug Combo That Eradicates Helicobacter Pylori Infection In Adults
Source: Gastroenterology News May 05, 2020 4 years, 6 months, 2 weeks, 1 day, 20 hours, 54 minutes ago
Gastroenterology: Medical researchers have developed a new treatment protocol involving a three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule called RHB-105 that effectively eradicates Helicobacter pylori infection in adults. The novel formulation was found to still be effective and well-tolerated in an environment of clinically significant antibiotic resistance.
Research findings from a double-blind randomized trial are published in
Annals of Internal Medicine.
https://annals.org/aim/article-abstract/2765671/rifabutin-based-triple-therapy-rhb-105-helicobacter-pylori-eradication-double
Helicobacter pylori infection is the main cause of gastrointestinal diseases, such as peptic ulcer, gastritis, and gastric cancer.
Present medical guidelines recommend eradication of the infection, but it is difficult to treat because success with previously effective therapies has declined, related largely to the worldwide increase in antibiotic resistance.
The WHO or World Health Organization and the US Food and Drug Administration (US FDA) have designated clarithromycin-resistant H pylori as a focus for new drug development, and the FDA included it as a pathogen with "the potential to pose a serious threat to public health."
Medical researchers at 55 clinical research sites in the United States, led by researchers from the Michael E. De-Bakey Veterans Affairs Medical Center, randomly assigned 455 treatment-naive adults with epigastric discomfort and confirmed H pylori infection to triple therapy with RBH-105 or dual therapy of amoxicillin/omeprazole to assess the effectiveness of RHB-105 for H pylori eradication.
The medical researchers found that H. pylori eradication rate was significantly greater following treatment with the rifabutin-based triple therapy than with high-dose amoxicillin/omeprazole dual therapy. Eradication rates were not affected by H. pylori resistance to clarithromycin or metronidazole, which suggests that RHB-105 should be considered as a first-line empirical therapy of H pylori infection.
The medical researchers are planning more clinical trials before submitting regulatory approvals to officially designate the protocol for H.pylori eradication and also to have it incorporated to various medical guidelines for the treatment of Helicobacter pylori infections and related diseases.
For the latest developments in the field of
Gastroenterology, keep logging to Thailand Medical News.
A Call For Help! Please help support to sustain this website and all our efforts to propel further research and also various international community projects by making a donation. Donations are accepted via paypal. https://www.thailandmedical.news/p/sponsorship
